Showing posts with label Quality of care. Show all posts
Showing posts with label Quality of care. Show all posts

July 4, 2013

Improving quality of care in patients with cirrhosis

Clinical Liver Disease Volume 2, Issue 3, pages 123–124, June 2013

Special Issue: Cirrhosis and Kidney Function

Review

Fasiha Kanwal*, Hashem El-Serag

Article first published online: 21 JUN 2013

DOI: 10.1002/cld.189

Copyright © 2013 the American Association for the Study of Liver Diseases

Abstract

Watch a video presentation of this article

Watch the interview with the author

Answer questions and earn CME

Abbreviations

EHR, electronic health records; SBP, spontaneous bacterial peritonitis.

Cirrhosis is a prevalent and expensive condition, affecting approximately 2.5 million individuals at a cost of over $4 billion annually in the United States.1–3 Cirrhosis is the second leading cause of digestive disease–related mortality, preceded only by colorectal cancer.3 The human and economic burden of cirrhosis is expected to increase substantially in the next 10 years as a result of an aging chronic hepatitis C population4 and the possible consequences of fatty liver disease.

Appropriate medical care for cirrhosis can delay complications, improve quality of life, and possibly extend survival.5–8 Experts commissioned by professional societies have published comprehensive evidence-based guidelines to help clinicians better manage these patients.9, 10 Existing data are sparse in the extent to which patients with cirrhosis receive guideline-recommended care, but few important studies indicate significant shortfalls.5, 11 In a cohort of 774 patients with cirrhosis and ascites seen at three Veterans Affairs Medical Centers between 2000 and 2007, we recently found that nearly all patients with documented spontaneous bacterial peritonitis (SBP) received antibiotics for treatment of SBP.12 However, only 30% of these patients received recommended antibiotics for secondary prophylaxis after their discharge from the hospital. In general, care targeted at diagnosis of acute events, especially with regard to hospitalized patients (e.g., paracentesis, ascitic fluid analysis) and treatment (e.g., antibiotics for documented SBP, diuretics), is more likely to meet guideline-recommended standards than preventive and more elective outpatient care (e.g., primary and secondary antibiotic prophylaxis for SBP), despite extensive data that preventive care improves outcomes in patients with cirrhosis.

The first step toward improving the quality of cirrhosis care is to try to measure it. Using a modified Delphi method, we developed a set of explicit quality indicators for patients with cirrhosis.13 These indicators can either be applied retrospectively (using preexisting data) or measured in real-time (at the time of clinical encounter). Regardless of the approach, the use of electronic health records (EHR)-based tools is likely to be important for efficient capture and reporting of quality measures. However, our studies show that the use of automated data that can be readily generated from EHR (such as diagnosis and procedure codes), while reasonably valid for some quality measures in cirrhosis, is fraught with errors for other indicators. For example, there are many reasons why patients do not receive recommended care, some of which are justifiable exceptions (e.g., presence of comorbidities, contraindications, and patient refusal).12 We found that for some of the cirrhosis quality indicators, preexisting data did not capture these exceptions to allow for accurate automated measurement.12 These results suggest that quality indicator measurement systems (such as EHR vendors) will need to incorporate ways of documenting justifiable exclusions. Clearly, more work is required to standardize and validate the methods of collecting cirrhosis quality indicators.

Quality measurement and reporting alone may not achieve higher quality care, and therefore efforts to improve care will need to target actionable drivers of timely cirrhosis care. Domains that can serve as potential targets for intervention at a practice level include providing better access to specialist care.12 Patient subgroups that may be important targets for future interventions include those with medical comorbidities.12 Our data also suggest that focused efforts on preventive care in ascites may improve quality of care delivered to patients with cirrhosis and ascites.12

Implementation of solutions and interventions will depend on the underlying problem as well as the structure and context of the clinical setting and practice needs (Table 1). Simpler interventions such as standardization (e.g., implementation of electronic order sets or care pathways) may be effective enough for situations that do not depend on the participation of many parties (such as ordering antibiotics in the setting of gastrointestinal bleeding and hepatocellular carcinoma screening). Designing a more expensive form of coordination may be necessary if the goal is to improve complex endpoints (such as hospital admission rates, morbidity, and mortality) that are dependent on many individuals, including patients, clinicians, caregivers, case managers, and so forth. We may also need to move toward new models of care in cirrhosis.14 These models include: (1) the application of elements of a chronic care model, in which active disease management continues in between clinic visits using home-based interventions such as home visits, scheduled telephone calls, and remote home monitoring systems; (2) multidisciplinary care, including gastroenterologists/hepatologists, primary care physicians, radiologists, infectious disease physicians and/or psychiatrists (who can either be colocated in a single clinic or actively engaged in cross-discipline collaboration via regular meetings [similar to tumor or transplant evaluation boards]); and (3) improving access to specialty care, particularly for patients with cirrhosis in underserved areas, via electronic consults and telemedicine. Although these models remain untested in patients with cirrhosis, their success in other areas of medicine suggest that they may improve outcomes in cirrhosis.

Table 1. Potential Interventions to Improve Quality of Care in Patients with Cirrhosis

 

Goal Intervention
  1. Implementation of interventions will depend on the underlying goals or problems as well as the structure and context of the clinical setting and practice needs.

Administration of antibiotics in all patients with cirrhosis and gastrointestinal bleeding Standardized electronic order sets
Screening for hepatocellular cancer Established care pathways
Reducing preventable hospital readmissions; improving morbidity and mortality Improving access to specialty care
Multidisciplinary care, including gastroenterologists/hepatologists, primary care physicians, radiologists, and psychiatrists
Case management, including home-based interventions such as home visits, scheduled telephone calls, and remote home monitoring systems

In our setting (an academically affiliated Veterans Administration Medical Center with a mature EHR), we are increasingly relying on clinical templates that incorporate clinical guidelines and small registries to monitor timely and consistent delivery of recommended preventive care (such as variceal screening, liver cancer screening, and vaccinations). We are expanding our clinical staff to include midlevel providers who, in addition to sharing the physicians' workload, are playing a major role in the coordination of patient care. We are also streamlining electronic communication between primary care providers and gastroenterologists through explicit follow-up recommendations for patients seen in the specialty clinic and detailed justification in cases where consults are discontinued. These are some examples of steps we are taking to improve quality of care delivered to patients with cirrhosis while waiting for more concrete evidence regarding the effectiveness of alternative care models in this population.

References

Source

June 24, 2013

Improving quality of care in patients with cirrhosis†

Clinical Liver Disease

Special Issue: Cirrhosis and Kidney Function

Volume 2, Issue 3, pages 123–124, June 2013

Review

Fasiha Kanwal*, Hashem El-Serag

Article first published online: 21 JUN 2013

DOI: 10.1002/cld.189

Copyright © 2013 the American Association for the Study of Liver Diseases

Abstract

Watch a video presentation of this article

Watch the interview with the author

Answer questions and earn CME

Abbreviations

EHR, electronic health records; SBP, spontaneous bacterial peritonitis.

Cirrhosis is a prevalent and expensive condition, affecting approximately 2.5 million individuals at a cost of over $4 billion annually in the United States.1–3 Cirrhosis is the second leading cause of digestive disease–related mortality, preceded only by colorectal cancer.3 The human and economic burden of cirrhosis is expected to increase substantially in the next 10 years as a result of an aging chronic hepatitis C population4 and the possible consequences of fatty liver disease.

Appropriate medical care for cirrhosis can delay complications, improve quality of life, and possibly extend survival.5–8 Experts commissioned by professional societies have published comprehensive evidence-based guidelines to help clinicians better manage these patients.9, 10 Existing data are sparse in the extent to which patients with cirrhosis receive guideline-recommended care, but few important studies indicate significant shortfalls.5, 11 In a cohort of 774 patients with cirrhosis and ascites seen at three Veterans Affairs Medical Centers between 2000 and 2007, we recently found that nearly all patients with documented spontaneous bacterial peritonitis (SBP) received antibiotics for treatment of SBP.12 However, only 30% of these patients received recommended antibiotics for secondary prophylaxis after their discharge from the hospital. In general, care targeted at diagnosis of acute events, especially with regard to hospitalized patients (e.g., paracentesis, ascitic fluid analysis) and treatment (e.g., antibiotics for documented SBP, diuretics), is more likely to meet guideline-recommended standards than preventive and more elective outpatient care (e.g., primary and secondary antibiotic prophylaxis for SBP), despite extensive data that preventive care improves outcomes in patients with cirrhosis.

The first step toward improving the quality of cirrhosis care is to try to measure it. Using a modified Delphi method, we developed a set of explicit quality indicators for patients with cirrhosis.13 These indicators can either be applied retrospectively (using preexisting data) or measured in real-time (at the time of clinical encounter). Regardless of the approach, the use of electronic health records (EHR)-based tools is likely to be important for efficient capture and reporting of quality measures. However, our studies show that the use of automated data that can be readily generated from EHR (such as diagnosis and procedure codes), while reasonably valid for some quality measures in cirrhosis, is fraught with errors for other indicators. For example, there are many reasons why patients do not receive recommended care, some of which are justifiable exceptions (e.g., presence of comorbidities, contraindications, and patient refusal).12 We found that for some of the cirrhosis quality indicators, preexisting data did not capture these exceptions to allow for accurate automated measurement.12 These results suggest that quality indicator measurement systems (such as EHR vendors) will need to incorporate ways of documenting justifiable exclusions. Clearly, more work is required to standardize and validate the methods of collecting cirrhosis quality indicators.

Quality measurement and reporting alone may not achieve higher quality care, and therefore efforts to improve care will need to target actionable drivers of timely cirrhosis care. Domains that can serve as potential targets for intervention at a practice level include providing better access to specialist care.12 Patient subgroups that may be important targets for future interventions include those with medical comorbidities.12 Our data also suggest that focused efforts on preventive care in ascites may improve quality of care delivered to patients with cirrhosis and ascites.12

Implementation of solutions and interventions will depend on the underlying problem as well as the structure and context of the clinical setting and practice needs (Table 1). Simpler interventions such as standardization (e.g., implementation of electronic order sets or care pathways) may be effective enough for situations that do not depend on the participation of many parties (such as ordering antibiotics in the setting of gastrointestinal bleeding and hepatocellular carcinoma screening). Designing a more expensive form of coordination may be necessary if the goal is to improve complex endpoints (such as hospital admission rates, morbidity, and mortality) that are dependent on many individuals, including patients, clinicians, caregivers, case managers, and so forth. We may also need to move toward new models of care in cirrhosis.14 These models include: (1) the application of elements of a chronic care model, in which active disease management continues in between clinic visits using home-based interventions such as home visits, scheduled telephone calls, and remote home monitoring systems; (2) multidisciplinary care, including gastroenterologists/hepatologists, primary care physicians, radiologists, infectious disease physicians and/or psychiatrists (who can either be colocated in a single clinic or actively engaged in cross-discipline collaboration via regular meetings [similar to tumor or transplant evaluation boards]); and (3) improving access to specialty care, particularly for patients with cirrhosis in underserved areas, via electronic consults and telemedicine. Although these models remain untested in patients with cirrhosis, their success in other areas of medicine suggest that they may improve outcomes in cirrhosis.

Table 1. Potential Interventions to Improve Quality of Care in Patients with Cirrhosis

Goal Intervention
Administration of antibiotics in all patients with cirrhosis and gastrointestinal bleeding Standardized electronic order sets
Screening for hepatocellular cancer Established care pathways
Reducing preventable hospital readmissions; improving morbidity and mortality Improving access to specialty care
Multidisciplinary care, including gastroenterologists/hepatologists, primary care physicians, radiologists, and psychiatrists
Case management, including home-based interventions such as home visits, scheduled telephone calls, and remote home monitoring systems

Implementation of interventions will depend on the underlying goals or problems as well as the structure and context of the clinical setting and practice needs.

In our setting (an academically affiliated Veterans Administration Medical Center with a mature EHR), we are increasingly relying on clinical templates that incorporate clinical guidelines and small registries to monitor timely and consistent delivery of recommended preventive care (such as variceal screening, liver cancer screening, and vaccinations). We are expanding our clinical staff to include midlevel providers who, in addition to sharing the physicians' workload, are playing a major role in the coordination of patient care. We are also streamlining electronic communication between primary care providers and gastroenterologists through explicit follow-up recommendations for patients seen in the specialty clinic and detailed justification in cases where consults are discontinued. These are some examples of steps we are taking to improve quality of care delivered to patients with cirrhosis while waiting for more concrete evidence regarding the effectiveness of alternative care models in this population.

References

Source

HCV Care in VA Debated

Provided by NATAP

Download the PDF here

Download the PDF here

Download the PDF here

below are a series of 3 letters to the editor debating the quality of care of HCV for vets in the VA which followed from the publication of this study criticizing HCV care in the VA

from Jules:
This publication in the J of Hepatolog.....led to this letter below to the Journal by Cecil Bennet, which in return led to a response below by David Ross, Director of HCV treatment at the VA, and then again another response below back from Cecil Bennet.

Gaps in the achievement of effectiveness of HCV treatment in national VA practice - "overall effectiveness of HCV therapy is low in a national sample of veterans with chronic HCV"

http://www.natap.org/2012/HCV/012312_03.htm

"There is a chasm between efficacy and effectiveness of antiviral treatment in the VA......The lack of treatment in the remaining patients is potentially concerning......a majority of patients never received a biopsy as part of their evaluation process, and therefore their fibrosis stage remains unknown thus lack of significant fibrosis does not seem to explain the low treatment rates in this population of HCV patients.......Only 11.6% of patients had a liver biopsy in the VA during the two years before and two years after their HCV index date......The study highlights the sporadic testing for viral counts among patients started on antiviral treatment, which does not allow for classifying patients to the conventional randomized trial definition.......39.8% were not tested for genotype......HCV genotype was unknown in 8.8% of the patients who received treatment......Patients who were not tested for genotype were significantly less likely to receive any antiviral treatment (3.3% vs. 25.2%, p <0.0001)......Approximately 43% of patients who did not receive antiviral treatment had none of the contraindications to treatment listed in Materials and methods and in Table 1"

Chronic

Click on picture to enlarge

Why 88% of US military veterans with HCV are not treated

Bennet Cecil
Jnl of Hepatology July 2013
Hepatitis C Treatment Centers, 1009A Dupont Square N, Louisville, KY 40207, USA To the Editor:

The article in the February issue of the Journal of Hepatology reported that less than 12% of American military veterans identified with HCV were treated with antiviral therapy [1]. The Veterans Administration does not want to spend adequate funds to cure patients with hepatitis C. Dr. Kenneth Kizer, Under Secretary for Health in the US Department of Veterans Affairs (VA), gave HCV a high priority but unfortunately he left the VA in 1999. Subsequent leadership has not shown enthusiasm for treating HCV.

The Director of Pharmacy and the Chief of Staff at my local VA hospital told me that I spent too much money treating HCV. Boceprevir and telaprevir are both on the hospital formulary but telaprevir prescriptions are routinely denied because it is more expensive. Patients must jump multiple hurdles before qualifying for antiviral therapy. No one would refuse to give coronary artery stents or bypass grafts to a veteran who smokes but veterans who do not completely abstain from alcohol for three months are refused antiviral therapy. In spite of difficulties, 585 of 1372 (43%) HCV RNA positive patients received antiviral therapy between 1998 and 2010 at our local VA hospital; 226 of 583 treated (39%) achieved SVR [2]. 36% of deaths were from HCC or liver failure. Veterans with sustained viral response had substantially improved survival. Effective antiviral therapy improves prognosis [3], [4]. Less than 2% of Americans die from liver disease, but more than one third of veterans with HCV die prematurely from complications of cirrhosis [2], [5]. According to a 2010 national VA report, deaths in veterans with HCV have more than tripled, "Between 2000 and 2008, the annual number of all cause deaths recorded for Veterans with chronic HCV rose from 1259 (1129 per 100,000 in VHA care) to 5967 (4049 per 100,000 in VHA care), respectively" [6].

Legislation should be passed allowing veterans with HCV to prequalify for their choice of Medicaid or Medicare so that they can obtain antiviral therapy in the private sector. Since Dr. Kizer is no longer in charge of the VA, it is very clear that the VA is not going to treat very many of them.

Treatment of veterans with hepatitis C in the United States Department of Veterans Affairs

Journal of Hepatology
July 2013

David Ross

To the Editor:
As Director of the National Hepatitis C Program for the United States Department of Veterans Affairs [VA], the largest provider of care in the United States for HCV, I would like to respond to the statements by Dr. Bennett Cecil in the October 2012 issue of the Journal of Hepatology about access to and quality of care for HCV-infected Veterans in VA care [1].

1.Dr. Cecil used data from 2005 [2] as the basis for his statement that only 12% of Veterans with HCV in VA care have received anti-viral therapy. However, two of the references he cited explicitly contradict that figure [3], [4]. In fact, the actual proportion treated is more than double that. As of September 30, 2012, internal VA data show over 25% of HCV-infected Veterans in VA care having received such treatment, compared to 17% in non-VA settings [5].

2.Dr. Cecil incorrectly states that both boceprevir and telaprevir are on the VA National Formulary; actually, only boceprevir is, with telaprevir available for use by VA providers as a non-formulary agent [6].

3.Dr. Cecil states that telaprevir is viewed as "too expensive" for use by VA but did not provide any evidence for this contention. In fact, a VHA policy memorandum issued in September 2011 stipulates that cost is not to be a factor in prescribing HCV protease inhibitors. Dr. Cecil did not provide an evidence-based rationale for his preference for prescribing telaprevir.

4.Dr. Cecil implies that he is responsible for anti-viral treatment of almost 600 HCV patients at the Louisville VA; however, multiple providers actually care for the patients with HCV infection at that facility. With regard to use of triple therapy at the Louisville VAMC, as of November 2012, 37 patients had initiated triple therapy (36 boceprevir, 1 telaprevir). Ten were on therapy at that time. Of the remaining 27, six (22.2%) had achieved an SVR, seven were discontinued for lack of efficacy, six were discontinued for toxicity, and eight for non-adherence.

5.The Louisville VAMC's screening/evaluation process includes a review by a clinical pharmacy specialist of drug/ drug interactions, current laboratory results, and monthly monitoring of prescription fills. Patients for whom treatment is appropriate attend a mandatory education class and provided information on HCV, anti-viral therapy, and drug side effects, as well as the importance of drug compliance and obtaining repeat laboratory tests. In addition, a treatment plan and follow-up clinic appointments are reviewed. This class is scheduled weekly, but also has been done at other times at the convenience of individual Veterans (M. Rothschild, personal communication).

Finally, and most importantly, Dr. Cecil's assertions that "VA has not shown enthusiasm for treating HCV patients" and that it is "not going to treat very many of them" are incorrect. Since FDA approved the first direct acting anti-virals in May 2011, VA has treated almost 4500 patients with triple therapy, spent over $100 million in antiviral drug acquisition costs, published updated treatment guidelines recommending use of regimens incorporating direct acting antivirals [7], trained hundreds of VA health care providers to deliver anti-viral therapy, championed integrated models to address treatment-limiting comorbidities [8], added dozens of clinical resources to its HCV Web site (www.hepatitis.va.gov), and moved aggressively to increase access to evaluation and treatment of HCV through teleconsultation models [9].

As a VA clinician who provides care for Veterans with HCV, I am proud of VA's HCV Program, which is recognized as a national leader in the integrated care of patients with this disease [10]. Although there is always room for improvement in any therapeutic service in any health care system, VA has been striving to deliver high-quality, evidence-based care to as many Veterans with HCV as possible, and will continue to do so.

Reply to: "Treatment of veterans with hepatitis C in the United States Department of Veterans Affairs"

Bennet Cecil

To the Editor:

I would like to thank Dr. Ross.

(1)Dr. Ross does not state how many veterans with HCV are currently receiving care at the Department of Veterans Affairs (VA). In 2008, VHA clinicians cared for over 147,000 veterans with chronic HCV [1]. Treating 4500 patients with HCV in 20 months is only 225 patients per month. The VA is currently treating less than 2% of infected veterans per year with boceprevir and telaprevir. It will take more than fifty years for the VA to treat all of their HCV infected patients. Evidence based care of an infectious disease is cure of the infection not the development of integrated models to address comorbidities. If 98% of patients with a curable infection are not treated each year, the VA's response is inadequate.

(2)The VA does a better job with the human immunodeficiency virus (HIV) treating 78% of veterans [2]. The number of patients on antiviral therapy clearly indicates that HIV is a high priority for the VA while HCV treatment is not.

(3)Telaprevir is not available as a non-formulary drug at the Louisville VA. Boceprevir is on the formulary there.

(4)More than 1800 patients with HCV antibodies have been identified at the Louisville VA over 19 years. They had multiple physicians providing care.

(5)$100 million for antiviral therapy over 20 months is $5 million per month. This is clearly inadequate to treat 147,000 veterans with hepatitis C. This is why legislation should be passed so that all veterans with HCV immediately prequalify for their choice of Medicaid or Medicare. They could then obtain antiviral therapy in the private sector instead of waiting for the VA to treat 2% of them each year. Now, many are trapped in the VA system while their curable infection progresses to liver cancer, liver failure and death.

Source